irbesartan / Generic mfg. - LARVOL DELTA

POEMS syndrome presenting as presumed chronic glomerulonephritis with a 1-year delay in diagnosis: a case report. (PubMed, Front Med (Lausanne)) - "She had previously been treated with irbesartan for presumed chronic glomerulonephritis...At follow-up, the patient was initiated on lenalidomide and dexamethasone therapy and is currently undergoing autologous stem cell transplantation at a tertiary care center, showing significant symptomatic improvement. In patients with an unexplained chronic glomerulonephritis-like presentation that is refractory to standard therapy, POEMS syndrome should be considered in the differential diagnosis, even in the absence of typical skin or bone changes. Early serum immunofixation and VEGF assessment are critical for avoiding a delayed diagnosis."

Journal • Cardiovascular • Endocrine Disorders • Glomerulonephritis • Lupus Nephritis • Musculoskeletal Pain • Nephrology • Oncology • Pain • Rare Diseases • Renal Disease • Transplantation

Low-Normal Hemoglobin Concentrations and Clinical Outcomes in Heart Failure. (PubMed, J Am Coll Cardiol) - P3 | "In patients with HF, hemoglobin concentrations associated with the lowest risk of death and HF hospitalization were approximately 14 g/dL in women and 15 g/dL in men. Hemoglobin concentrations above WHO anemia thresholds may still carry prognostic information and, in conjunction with other clinical findings, may prompt consideration of potentially reversible contributors such as iron deficiency. (Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity [CHARM-Added], NCT00634309; Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity [CHARM-Alternative], NCT00634400; Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity [CHARM-Preserved], NCT00634712; A Comparison Of Outcomes In Patients In New York Heart Association [NYHA] Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines [EMPHASIS-HF], NCT00232180; Irbesartan in..."

Clinical data • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Disorders

Xiaoshen formula delays progression of diabetic kidney disease and improves glucose and lipid metabolism: Association with the JAK/STAT pathway. (PubMed, Pak J Pharm Sci) - "This study provides experimental evidence that XSF may delay early DKD progression. XSF ameliorates fasting blood glucose, stabilizes body weight, improves glucose/lipid metabolism and attenuates renal injury and no obvious hepatorenal toxicity under limited conditions. Findings suggest that XSF delays DKD progression may be associated with modulation of the JAK/STAT signaling pathway and inhibition of renal fibrosis."

Journal • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Dyslipidemia • Fibrosis • Gastrointestinal Disorder • Immunology • Metabolic Disorders • Nephrology • Renal Disease • JAK2 • PPARG • STAT6 • TGFB1

Advances in Treatment and Management of FSGS (KIDNEY WEEK 2026) - "The US Food and Drug Administration approved sparsentan in April 2026 as the DUPLEX trial data demonstrated greater sustained proteinuria reduction compared to irbesartan, reinforcing proteinuria as a meaningful therapeutic target and providing a new treatment option for patients. Support is provided by an educational grant from Travere Therapeutics, Inc. Learning Objective(s) Define the importance of proteinuria as a driver of disease in FSGS and its potential to accelerate approval of novel therapies Summarize emerging approaches to address the mechanisms driving eGFR loss in FSGS Evaluate large-scale analyses from the PARASOL Project"

Focal Segmental Glomerulosclerosis • Glomerulonephritis • Renal Disease

Using physiologically based pharmacokinetic modelling to optimize repaglinide and irbesartan dosing in Chinese population with SLCO1B1 polymorphism. (PubMed, Br J Clin Pharmacol) - "A PBPK model was built for REP and IRB and used to predict DDI for the population with SLCO1B1 c.521 T > C gene polymorphism. Moreover, the model was applied to provide individualized drug recommendations for the SLCO1B1 c.521TT genotype population."

Journal • PK/PD data

Irbesartan Promotes Retinal Ganglion Cell Survival and Modulates Mitochondrial and Inflammatory Pathways in Mouse Retinal Explant and in Optic Nerve Crush Models. (PubMed, Am J Pathol) - "RNA-sequencing revealed differential expression of electron transport chain (ETC) genes (e.g., Cox4i2, Ndufa12), with gene set enrichment analysis (GSEA) showing enrichment of proinflammatory pathways in vehicle-treated explants and neuronal/ metabolic pathways with irbesartan. In conclusion, irbesartan reduces oxidative stress, and modulates mitochondrial and inflammatory pathways potentially supporting RGC survival thus providing insights relevant to glaucoma and optic neuropathies involving RGC degeneration."

Journal • Preclinical • CNS Disorders • Glaucoma • Ocular Inflammation • Ophthalmology • Optic Neuritis • RBPMS

Antihypertensive Efficacy and Safety of Angiotensin Receptor Blockers (ARBs) with and without Inverse Agonism: A Systematic Review and Network Meta-analysis. (PubMed, Am J Cardiovasc Drugs) - "This study supports that ARBs with inverse agonism, especially AZL-M, have a better BP-lowering efficacy compared with ARBs without inverse agonism and ARNIs, while maintaining favorable safety profiles. Future research is encouraged to explore the effects on long-term outcomes, combination therapies, and safety in diverse populations."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Hypertension

Approved therapies in the IgA nephropathy armamentarium: a summary of the evidence. (PubMed, Kidney Int Suppl (2011)) - "Recent approvals include Nefecon, sparsentan, iptacopan, atrasentan, and sibeprenlimab. Nefecon, a targeted-release formulation of budesonide, is the only US Food and Drug Administration and European Medicines Agency fully approved agent that is designed to target the primary source of IgAN: galactose-deficient IgA1 production in the gut mucosa...Sparsentan demonstrated a significant reduction in proteinuria and estimated glomerular filtration rate decline compared with irbesartan...The endothelin A receptor antagonist atrasentan and A proliferation binding ligand inhibitor sibeprenlimab have also received accelerated US Food and Drug Administration approval, based on interim phase 3 results showing significant proteinuria reduction versus placebo in patients with IgAN. This expanded clinical armamentarium offers clinicians and patients greater choice and improved disease control in IgAN management."

Journal • Review • Fibrosis • Glomerulonephritis • IgA Nephropathy • Immunology • Inflammation • Renal Disease • CFB

Removal of organic micropollutants in granular activated carbon filters - review of long-term and full-scale experiences from municipal wastewater treatment. (PubMed, Water Sci Technol) - "Breakthrough of indicator compounds varied widely, but citalopram, metoprolol, benzotriazole, and methylbenzotriazole generally showed relatively late breakthrough, indicating potential for longer filter lifespan, whereas candesartan and irbesartan more often showed early breakthrough. However, the limited number of long-term full-scale studies and the large variability in pre-treatment, filter design, carbon type, and operating conditions prevent robust quantitative assessment of these relationships. The findings highlight the need for more large-scale, long-term studies using a systematic evaluation framework to support the effective implementation of GAC filtration for UWWTD compliance."

Journal • Review

Bridging pathogenesis and therapy in focal segmental glomerulosclerosis: the rise of dual receptor blockade with sparsentan. (PubMed, Ann Med Surg (Lond)) - "Although sparsentan did not demonstrate a statistically significant benefit in preserving estimated glomerular filtration rate, it achieved a clinically meaningful reduction in proteinuria compared with irbesartan. While sparsentan introduces a novel, non-immunosuppressive therapeutic option, its long-term impact on renal outcomes remains to be fully established. Ongoing research will be critical to defining its role within combination regimens and optimizing patient selection in this complex disease spectrum."

Journal • Chronic Kidney Disease • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Hypotension • Nephrology • Renal Disease

Metabolic Dysregulation of FC3 Fibrochondrocytes via MDH2 Promotes Intervertebral Disc Degeneration. (PubMed, J Cell Mol Med) - "Drug screening identified several candidate compounds, including Platycodin D, Irbesartan, and Ergothioneine, whose corresponding targets exhibited specifically enhanced activity within the FC3 (metabolic) subpopulation of degenerated tissues. Our study reveals that metabolic dysregulation in the FC3 fibrochondrocyte subpopulation, driven by aberrant MDH2-mediated TCA cycle activation, is a critical mechanism promoting IDD. These findings highlight the therapeutic targeting value of the FC3 metabolic state and provide specific candidate compounds for the subsequent development of interventions against IDD."

Journal • Back Pain • Fibrosis • Lumbar Back Pain • Metabolic Disorders • Musculoskeletal Pain • Pain

Retrospective non-target screening reveals the occurrence and environmental risk of pharmaceutical transformation products in the Pearl River Basin. (PubMed, Environ Int) - "Notably, the TP SR-49498 showed a significantly higher environmental risk quotient (RQ = 13.271) than its parent Irbesartan (RQ < 0.0001). Toxicological Priority Index (ToxPi) analysis prioritized 12 high-risk TPs. Overall, this study systematically characterized the occurrence and environmental risks of pharmaceutical TPs in the PRB, thereby advancing the understanding of their environmental fate and providing a scientific basis for future water pollution monitoring and risk management strategies."

Journal • Retrospective data

IgA nephropathy shortly follwed by seroconversion of positive anti-GBM antibodies and rapid progressive glomerulonephritis in a Chinese boy: coincidental overlap or pathogenic link? (PubMed, BMC Nephrol) - "We report a pediatric male case in whom anti-glomerular basement membrane disease developed secondarily during the clinical course of IgA nephropathy. This case strongly suggests that in patients with newly diagnosed chronic glomerulonephritis, such as IgA nephropathy, a high index of suspicion for concurrent autoimmune diseases including anti-glomerular basement membrane disease should be maintained when rapid progression of glomerulonephritis occurs."

Journal • Glomerulonephritis • IgA Nephropathy • Immunology • Lupus Nephritis • Nephrology • Pediatrics • Renal Disease

Irbesartan ameliorates high‑glucose‑induced epithelial‑mesenchymal transition by downregulating the expression of NLRP3 in HK‑2 cells. (PubMed, Mol Med Rep) - "These results indicated that high glucose stimulation upregulated the expression of NLRP3 in HK‑2 cells and promoted the expression of EMT‑associated factors. Irbesartan inhibited the activation of the NLRP3 inflammasome and downregulated the expression of EMT‑related factors, which provided a basis for potential new strategies for the treatment of diabetic nephropathy."

Journal • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • CASP1 • CDH2 • NLRP3 • VIM

SPARX and SPARTAN Cohort B: Trials in Progress Evaluating Sparsentan for Recurrent or De Novo Focal Segmental Glomerulosclerosis and Immunoglobulin A Nephropathy Following Kidney Transplant (ATC 2026) - P2, P4 | "*Purpose: Sparsentan (SPAR), a dual endothelin angiotensin receptor antagonist (DEARA), demonstrated rapid and sustained proteinuria reduction compared with maximum labeled dose irbesartan in patients (pts) with native kidney IgA nephropathy (IgAN) or focal segmental glomerulosclerosis (FSGS) in the phase 3 PROTECT and DUPLEX trials, respectively. These studies will evaluate the safety and efficacy of SPAR in pts with IgAN or FSGS following a kidney transplant."

Chronic Kidney Disease • Focal Segmental Glomerulosclerosis • Glomerulonephritis • IgA Nephropathy • Renal Disease • Transplantation

Case Report: Successful treatment of Bartonella henselae-associated crescentic glomerulonephritis in renal transplant recipient. (PubMed, Front Med (Lausanne)) - "The patient received azithromycin (500 mg/day for 5 days) for infection and corticosteroids (5 mg/kg pulse followed by a tapering regimen) for glomerulonephritis...Nephroprotective therapy was optimized (irbesartan up titrated from 75 to 150 mg/days and dapagliflozin 10 mg/day introduced), leading to normalization of proteinuria (UPCR 0.5 g/g) at 1-year follow-up...It also highlights the effectiveness of combined antibiotic and corticosteroids therapies in managing infectious glomerulonephritis. Clinicians should consider Bartonella as a potential etiology in renal transplant patients with CrGN, even in the absence of classic symptoms."

Journal • Acute Kidney Injury • Cardiovascular • Gastroenterology • Glomerulonephritis • Hypertension • Infectious Disease • Lupus Nephritis • Nephrology • Renal Disease • Transplantation

Sparsentan for the Treatment of Immunoglobulin A Nephropathy: An Innovative Concept for Economic Modelling. (PubMed, J Clin Med) - " A cohort-level state transition model was developed, comparing the health benefits of sparsentan, a dual endothelin angiotensin receptor antagonist, to irbesartan, an angiotensin receptor blocker, in IgAN. This study presents a new structure for health economic models in IgAN that more comprehensively captures the effect of proteinuria in combination with CKD progression. This new approach ultimately allows for the more robust implementation of clinical trial data in IgAN and estimates of the cost-effectiveness of new treatments."

Journal • Chronic Kidney Disease • Glomerulonephritis • IgA Nephropathy • Nephrology • Renal Disease

The State of Imidazolone as an Evolving Pharmacophore: Current Progress and Clinical Significance in Oncology and AMR. (PubMed, ACS Omega) - "Nevertheless, the significant therapeutic and clinical efficacy of imidazolone-bearing drugs, such as Nilutamide, Irbesartan, and Leucettinib-21, in anticancer, antihypertensive, and neurotherapeutic applications has stimulated increasing interest in imidazolone chemistry and its medicinal potential. The convergence of in silico predictions with experimental findings offers valuable guidance for the rational development of imidazolone-based therapeutics. Overall, this review emphasizes imidazolones as promising scaffolds with significant potential for future drug discovery and development."

Journal • Review • Oncology • Solid Tumor • BCL2 • EGFR

AIFA-CARDIO-129: Pharmacological optimization in prevention in Heart Failure: A Sex-gap? (clinicaltrialsregister.eu) - P4 | N=368 | Recruiting | Sponsor: Policlinico San Donato S.p.A. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Congestive Heart Failure • Heart Failure

Rapid quantification method of pharmaceuticals in urban wastewater using UHPLC-Orbitrap mass spectrometry-a multi-target approach for EU-directive advanced treatment evaluation. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Limits of quantification (LOQ) ranged mostly between 15 and 30 ng/L, except for candesartan, irbesartan, and diclofenac with LOQ > 50 ng/L. Furthermore, the method was successfully applied to raw and treated wastewater from wastewater treatment plants (WWTPs) in the Saxon-Czech border region, which differ in terms of wastewater throughput and population equivalents. As a result, this method offers a rapid quantification approach for assessing the removal efficiency of pharmaceuticals and potential substitutes categorised in the UWWTD."

Journal

Sparsentan Versus Irbesartan in Pediatric Patients With FSGS. (PubMed, Kidney Int Rep) - P3 | "Sparsentan and irbesartan had similar safety profiles, with comparable incidence and severity of adverse events. In this post hoc analysis of pediatric patients with FSGS, sparsentan was generally well tolerated and clinically meaningful reductions in proteinuria were observed, consistent with the overall DUPLEX population."

Journal • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Pediatrics • Renal Disease

Effect of dapagliflozin-spironolactone combination therapy versus monotherapy on albuminuria reduction and hyperkalemia risk in elderly patients with early type 2 diabetic nephropathy receiving high-dose RASi: A randomized controlled trial. (PubMed, Am J Med Sci) - "In elderly patients with early DN on high-dose RASi, dapagliflozin-spironolactone combination therapy achieved superior albuminuria reduction compared with either monotherapy, while attenuating the risk of spironolactone-associated hyperkalemia. Although no case of hyperkalemia occurred in the combination group in our trial, serum potassium was notably elevated relative to dapagliflozin monotherapy, underscoring the importance of regular monitoring in this population."

Journal • Monotherapy • Cardiovascular • Diabetes • Diabetic Nephropathy • Hypertension • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Antihypertensive and anti-ischemic effects of diltiazem in patients with primary hypertension. (PubMed, Medicine (Baltimore)) - "Patients were assigned to 1 of 4 treatment groups: benazepril monotherapy group (benazepril 10 mg/day, n = 44); irbesartan monotherapy group (irbesartan 150 mg/day, n = 45); diltiazem monotherapy group (diltiazem hydrochloride sustained-release tablets 90 mg/day, n = 36); and combination therapy group (diltiazem hydrochloride sustained-release tablets 90 mg/day plus either benazepril 10 mg/day or irbesartan 150 mg/day, n = 35). Combination therapy with diltiazem and other antihypertensive agents, particularly benazepril, may offer additional therapeutic benefits. These findings support the potential role of diltiazem in the management of patients with mild to moderate hypertension and subclinical myocardial ischemia."

Journal • Observational data • Cardiovascular • CNS Disorders • Depression • Hypertension • Myocardial Ischemia • Psychiatry

Chemokine-Receptor Modulation Shapes Neuroinflammatory and Biomechanical Responses in Organotypic Hippocampal Cultures After Oxygen-Glucose Deprivation. (PubMed, ACS Chem Neurosci) - "These analyses revealed that Irbesartan treatment is associated with cytoskeletal reorganization and significant alterations in the mechanical properties of ischemic brain tissue. In summary, our study establishes the organotypic hippocampal culture-oxygen-glucose deprivation model as a robust platform for investigating neuroinflammatory processes in ischemic stroke. We identify key chemokine-receptor circuits that modulate ischemic injury and uncover a previously underappreciated contribution of tissue biomechanics to the pathophysiological response to ischemia."

Journal • Cardiovascular • CNS Disorders • Inflammation • Ischemic stroke • Vascular Neurology • CCR2 • CX3CR1 • CXCR4

Drug related nitrosogenesis, nitroso- photocarcinogenesis and the sertraline induced nevus associated cutaneous melanoma: spotlight on the nitrosocontamination as possible key triggering factor in relation to skin cancer pathogenesis (EADV-Sp 2026) - "Or reciprocal to that in valsartan, irbesartan, olmesartan, repeatedly described already as possible melanoma inducers. Conclusions According to the literature search, this is also the first case in the world of Sertraline-induced nevus associated cutaneous melanoma, and we share the view/ thesis that the possible real inducer of the tumor is in fact the impurities in the medication in the form of contaminants or nitrosamines: the so-called NDSRIs. The drug related nitrosogenesis/ Nitroso Photocarcinogenesis of skin cancer seems to be a more than significant concep regarding the pathogenesis of skin cancer that has been cleverly concealed by the scientific community until recently."

Cutaneous Melanoma • Genetic Disorders • Genito-urinary Cancer • Head and Neck Cancer • Kidney Cancer • Liver Cancer • Melanoma • Oncology • Renal Cell Carcinoma • Skin Cancer • Solid Tumor